“There is a low chance for olmesartan therapies to cause trouble in Korea”

The Korean Society of Hypertension turned in “Reply to the French Olmesartan Issue” to the Ministry of Food and Drug Safety(MFDS) on April 19.

The reply is a follow-up of the MFDS’s request for the “Opinions and Data about Necessity of Domestic Measures and Substitute Therapies regarding the French ANSM’s Measure.”

The society stated, “The U.S. FDA has already made a conclusion that it has n...